255 related articles for article (PubMed ID: 25834334)
1. Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B.
Jia HY; Ding F; Chen JY; Lian JS; Zhang YM; Zeng LY; Xiang DR; Yu L; Hu JH; Yu GD; Cai H; Lu YF; Zheng L; Li LJ; Yang YD
World J Gastroenterol; 2015 Mar; 21(12):3657-62. PubMed ID: 25834334
[TBL] [Abstract][Full Text] [Related]
2. Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety.
Lian JS; Zhang XL; Lu YF; Chen JY; Zhang YM; Jia HY; Zhang Z; Yang YD
Int J Med Sci; 2019; 16(1):17-22. PubMed ID: 30662324
[No Abstract] [Full Text] [Related]
3. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
[TBL] [Abstract][Full Text] [Related]
4. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
[TBL] [Abstract][Full Text] [Related]
5. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.
Tanaka M; Suzuki F; Seko Y; Hara T; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Gastroenterol; 2014 Mar; 49(3):470-80. PubMed ID: 23525978
[TBL] [Abstract][Full Text] [Related]
6. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy.
Lee M; Oh S; Lee HJ; Yeum TS; Lee JH; Yu SJ; Kim HY; Yoon JH; Lee HS; Kim YJ
J Viral Hepat; 2014 Dec; 21(12):873-81. PubMed ID: 24351112
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
[TBL] [Abstract][Full Text] [Related]
8. [Changes in serum β2-microglobulin, retinol-binding protein, and cystatin C and their value in identifying early renal dysfunction in patients with chronic hepatitis B undergoing tenofovir or entecavir monotherapy: a comparative analysis].
He J; Ning HB; Zeng YL; Li W; Li K; Shang J
Zhonghua Gan Zang Bing Za Zhi; 2016 Sep; 24(9):643-646. PubMed ID: 27788718
[No Abstract] [Full Text] [Related]
9. Telbivudine and adefovir dipivoxil combination therapy improves renal function in patients with chronic hepatitis B: A STROBE-compliant article.
Xu Y; Nie ZW
Medicine (Baltimore); 2018 Nov; 97(48):e13430. PubMed ID: 30508954
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.
Peng H; Liu J; Yang M; Tong S; Yin W; Tang H; Hu P; Hu H; Ren H
J Clin Pharmacol; 2014 Feb; 54(2):189-200. PubMed ID: 24105676
[TBL] [Abstract][Full Text] [Related]
12. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D
Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001
[TBL] [Abstract][Full Text] [Related]
13. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil.
Ha NB; Ha NB; Garcia RT; Trinh HN; Vu AA; Nguyen HA; Nguyen KK; Levitt BS; Nguyen MH
Hepatology; 2009 Sep; 50(3):727-34. PubMed ID: 19517525
[TBL] [Abstract][Full Text] [Related]
14. De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.
Yang S; Xing H; Wang Q; Wang X; Liu S; Cheng J
Ann Clin Microbiol Antimicrob; 2016 Apr; 15():24. PubMed ID: 27079793
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice.
Lin MT; Yen YH; Tsai MC; Tseng PL; Chang KC; Wu CK; Hu TH
PLoS One; 2016; 11(11):e0165416. PubMed ID: 27806120
[TBL] [Abstract][Full Text] [Related]
16. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
Wang JC; He LL; Chen Q
Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
[TBL] [Abstract][Full Text] [Related]
17. Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients.
Kim YJ; Cho HC; Sinn DH; Gwak GY; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
J Gastroenterol Hepatol; 2012 Feb; 27(2):306-12. PubMed ID: 21777281
[TBL] [Abstract][Full Text] [Related]
18. Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B.
Shimizu M; Furusyo N; Ikezaki H; Ogawa E; Hayashi T; Ihara T; Harada Y; Toyoda K; Murata M; Hayashi J
World J Gastroenterol; 2015 Feb; 21(7):2116-23. PubMed ID: 25717246
[TBL] [Abstract][Full Text] [Related]
19. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
20. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
